Conference starts in:

Learn more about our Virtual Reality project

Welcome to visit Open Karelia

You are here

The CULPRIT-SHOCK trial: breakthrough findings for the treatment of heart attack patients with cardiogenic shock

Heart attacks with cardiogenic shock represent a major European healthcare concern with mortality rates between 40-70%. So how can it be treated best? The breakthrough findings of the five-year long CULPRIT-SHOCK multi-center study give a clear answer to this question and even lead to a change of the Guidelines of the European Society of Cardiology.